CareDx, Inc. CDNA
Set alert
At close · Oct 30
After hours · Oct 30, 5:53 PM ET
- YTD
- +363.96%
- 1 year
- +504.08%
- Open
- 82.10
- Prev close
- 71.52
- Mkt cap
- 4.52B
- Vol
- 3.55M
- Avg vol
- 1.29M
- EPS
- 2.08
- P/E
- 42.02
- Div yield
- 0.00%
More statistics
- Low
- 81.22
- High
- 90.87
- Forward P/E
- 67.76
- Beta
- 2.38
- Short ratio
- 4.56
- Inst. own
- 102.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 59.12
- 200-d avg
- 33.31
- 1y target
- 65.33
3M chart
Events in this range
- Aug 6, 2026Rating: BTIG · Buy → Buy
- Sep 2, 2026Rating: Canaccord Genuity · — → Buy
- Sep 24, 2026Rating: BTIG · Buy → Buy
- Oct 19, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 27, 2026Rating: BTIG · Buy → Buy
- Oct 29, 2026Earnings: 0.7; estimate 0.2548; surprise 174.73%
- Oct 30, 2026Rating: BTIG · Buy → Buy
Signals (11)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 2026 | 1 day ago |
| MACD: Buy Signal | Oct 28, 2026 | 3 days ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| RSI: Overbought | Sep 16, 2026 | 1 month ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
| RSI: Overbought | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 4.52B
- Enterprise value
- 3.35B
- Trailing P/E
- 42.02
- Forward P/E
- 67.76
- PEG ratio
- 0.00
- Price / sales
- 9.87
- Price / book
- 10.57
- EPS (TTM)
- 2.08
- Beta
- 2.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 24.23%
- Revenue (TTM)
- 458.09M
- Revenue growth
- 52.20%
- Free cash flow
- 112.16M
- Total cash
- 373.64M
- Total debt
- 19.25M
- Return on equity
- 29.49%
- Shares outstanding
- 51.73M
- Short % of float
- 13.23%
- 50-day average
- 59.12
- 200-day average
- 33.31
Analyst view
Consensus: buy
- Target (low)
- 46.00
- Target (mean)
- 65.33
- Target (high)
- 81.00
- Strong buy0
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.23167.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.24 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.2548 | 0.70 | +0.45 | +174.73% |
| Jul 30, 2026 | Jun 30, 2026 | 0.2321 | 0.37 | +0.14 | +59.41% |
| Apr 28, 2026 | Mar 31, 2026 | 0.11 | 0.34 | +0.23 | +209.09% |
| Feb 24, 2026 | Dec 31, 2025 | 0.0199 | 0.12 | +0.10 | +503.02% |
| Nov 4, 2025 | Sep 30, 2025 | -0.08192 | 0.0319 | +0.11 | +138.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | BTIG | main | Buy | Buy |
| Oct 27, 2026 | BTIG | main | Buy | Buy |
| Oct 19, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 24, 2026 | BTIG | main | Buy | Buy |
| Sep 2, 2026 | Canaccord Genuity | init | — | Buy |
| Aug 6, 2026 | BTIG | main | Buy | Buy |
About CareDx, Inc.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- caredx.com
News
- Why CareDx Stock Soared Today
- 12 Health Care Stocks Moving In Friday's Intraday Session
- AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday
- CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
- Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
- What CareDx (CDNA) Said on Its Q3 Earnings Call
- CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- CareDx Raises FY2026 Sales Guidance from $490.000M-$500.000M to $520.000M-$530.000M vs $489.692M Est
- CareDx Q3 Adj. EPS $0.70 Beats $0.25 Estimate, Sales $139.362M Beat $120.608M Estimate
Your note
Sign in to keep a note on CDNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BICKERSTAFF GEORGE W III | Director | Sale | Aug 4, 2026 | 134,061 |
| COHEN FREDERICK E. M.D. PH.D. | Director | Stock Award(Grant) | Jun 11, 2026 | 165,060 |
| GOLDBERG MICHAEL D | Director | Stock Award(Grant) | Oct 1, 2026 | 153,371 |
| HANNA JOHN WALTER JR | Chief Executive Officer | Sale | Jul 15, 2026 | 653,448 |
| JAIN ABHISHEK | Chief Financial Officer | Sale | Apr 6, 2025 | 337,418 |
| KENNEDY KEITH S | Chief Operating Officer | Stock Award(Grant) | Apr 19, 2026 | 221,548 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.31% | 4,814,709 | 420.85M | Jun 29, 2026 |
| State Street Corporation | 4.77% | 2,468,858 | 215.80M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.25% | 2,197,475 | 192.08M | Jun 29, 2026 |
| Deerfield Management Company, L.P | 3.86% | 1,997,618 | 174.61M | Jun 29, 2026 |
| ARK Investment Management, LLC | 3.78% | 1,953,531 | 170.76M | Jun 29, 2026 |
| Boston Partners | 3.75% | 1,937,601 | 169.37M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,554,868 | 135.91M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.91% | 1,504,845 | 131.54M | Sep 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 2.66% | 1,373,550 | 120.06M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 1,329,541 | 116.22M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.55% | 1,321,241 | 115.49M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 588,494 | 51.44M | Jun 29, 2026 |